A synthetic heptapeptide with anxiolytic and nootropic properties developed in Russia, based on the endogenous immunomodulatory tetrapeptide tuftsin.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1990s and early 2000s. Its development was deliberate and methodical: researchers began with tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from immunoglobulin G that is produced in the spleen and known for its immunomodulatory properties, then modified it structurally to enhance stability and broaden its pharmacological profile. The result was a compound with a chemical structure of Thr-Lys-Pro-Arg-Pro-Gly-Pro — essentially the tuftsin backbone extended at the C-terminus with a Pro-Gly-Pro tripeptide sequence that significantly increases metabolic resistance to enzymatic degradation.
This structural addition turned out to be pharmacologically consequential in ways beyond simple stabilization. The extended peptide demonstrated a substantially different and richer activity profile than tuftsin alone, exhibiting pronounced anxiolytic effects that were absent or minimal in the parent compound. This discovery oriented subsequent research squarely toward central nervous system applications, and Selank eventually accumulated sufficient preclinical and clinical data to achieve approval in Russia as an anxiolytic and nootropic drug, where it is available as a nasal spray under the designation IP-15.
What makes Selank particularly interesting from a research standpoint is the character of its anxiolytic effect. Unlike benzodiazepines, which reduce anxiety through broad potentiation of GABA-A receptor activity and carry well-documented risks of sedation, cognitive impairment, tolerance, and physical dependence, Selank produces anxiolytic effects through a mechanistically distinct pathway that appears to spare or even enhance cognitive function. Study subjects and research participants have consistently reported reduction in anxiety without the clouding of cognition, muscle relaxation, or sedation that characterize benzodiazepine use — a profile sometimes described as “anxiolytic without anxiolysis of thought.”
The molecular weight of Selank is approximately 751.9 daltons, and its amino acid sequence (H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH) gives it physical characteristics suitable for intranasal delivery, which is the primary administration route studied and used clinically. Intranasal administration allows direct delivery to the central nervous system via olfactory and trigeminal pathways, bypassing significant first-pass metabolism and achieving CNS bioavailability without injection.
Selank continues to be actively researched for a range of applications including generalized anxiety disorder, cognitive enhancement under stress, immune modulation, and potentially as an adjunct in addiction medicine and post-traumatic stress. Its dual anxiolytic-nootropic profile places it in a therapeutic category with very few pharmacological competitors, making it a subject of sustained scientific interest well beyond its Russian market origins.
Brain-derived neurotrophic factor is among the most studied and functionally important neurotrophins in the central nervous system. BDNF supports the survival, growth, and differentiation of neurons; promotes synaptic plasticity; and is critically involved in the cellular mechanisms of learning, memory consolidation, and stress resilience. BDNF signals primarily through its high-affinity receptor TrkB (tropomyosin receptor kinase B), a receptor tyrosine kinase whose activation sets off intracellular cascades including the MAPK/ERK pathway (involved in synaptic plasticity and long-term potentiation) and the PI3K/Akt pathway (involved in neuronal survival and anti-apoptotic signaling).
Studies examining Selank’s effects on gene expression in the hippocampus and prefrontal cortex have found significant upregulation of BDNF mRNA and protein levels following administration, particularly in brain regions that are densely innervated by circuits regulating anxiety, stress responses, and cognitive function. The mechanistic link between BDNF elevation and anxiolytic-like behavior has been well established in separate lines of research: animals with reduced hippocampal BDNF show exaggerated anxiety responses to stress, and interventions that increase BDNF — including antidepressants, exercise, and environmental enrichment — consistently reduce anxiety-like behavior. Selank’s BDNF-elevating effect may therefore represent a primary mechanism through which it produces both its anxiolytic and its cognitive-enhancing effects, via shared TrkB downstream signaling.
One of the more pharmacologically distinctive features of Selank is its ability to modulate enkephalin degradation. Enkephalins are endogenous pentapeptides (met-enkephalin: Tyr-Gly-Gly-Phe-Met; leu-enkephalin: Tyr-Gly-Gly-Phe-Leu) that serve as endogenous ligands at delta and mu opioid receptors and are normally rapidly inactivated by enkephalinase enzymes (primarily neprilysin/neutral endopeptidase and aminopeptidase N) within seconds of release.
Research from Russian laboratory groups has demonstrated that Selank inhibits these enkephalin-degrading enzymes, effectively prolonging the half-life and signaling duration of endogenously released enkephalins. The consequence is an amplification of endogenous opioid tone that is self-regulated — it requires actual enkephalin release (triggered by stress, social interaction, or other relevant stimuli) rather than providing a tonic baseline opioid agonism. This mechanism is fundamentally different from exogenous opioid administration and carries quite different implications for tolerance and dependence. The opioid receptors activated by prolonged enkephalin signaling in limbic regions including the amygdala and nucleus accumbens are well-positioned to modulate anxiety and stress responses, and the delta opioid receptor in particular has been identified in multiple studies as an anxiolytic target with a favorable tolerability profile.
The complete mechanistic picture of Selank’s anxiolytic action likely involves more than BDNF and enkephalins. Electrophysiological studies have identified modulation of GABA-A receptor currents in neurons following Selank application, though the binding site and precise mechanism remain less fully characterized than those of classical benzodiazepines. The effect appears to involve potentiation of inhibitory GABA-ergic transmission in a way that is regionally selective and lacks the pan-GABAergic enhancement profile that underlies benzodiazepine-associated sedation and cognitive suppression. This regional selectivity — if confirmed by further structural and pharmacological studies — would provide a mechanistic explanation for why Selank produces anxiolysis without the sedative and amnestic effects of benzodiazepines.
Beyond GABA, Selank has been found to alter the metabolism of serotonin in brain regions critical for mood and anxiety. Studies measuring serotonin turnover ratios (5-HIAA/5-HT) in the hippocampus, frontal cortex, and striatum found changes consistent with normalization of aberrant serotonergic signaling rather than simple agonism or antagonism at specific 5-HT receptor subtypes. This is reminiscent of the mechanism proposed for SSRIs in anxiety disorders — not direct acute anxiolysis but gradual normalization of serotonin system dysregulation — though the timeline of Selank’s effect is substantially faster than typical SSRI clinical response, suggesting different kinetics even if serotonin is involved.
The most clinically relevant research on Selank involves its use in human subjects with generalized anxiety disorder (GAD), a condition characterized by persistent, difficult-to-control worry across multiple life domains accompanied by physical symptoms including muscle tension, fatigue, and sleep disturbance. Russian clinical trials examining Selank in GAD patients have used intranasal administration of 400-900 mcg per day (divided into multiple doses) over periods of 10-14 days, with outcomes assessed using validated rating scales including the Hamilton Anxiety Scale (HAM-A) and related instruments.
The findings from these trials have consistently demonstrated significant reductions in anxiety scores compared to baseline, with effect sizes comparable to those reported for benzodiazepines in similar studies. Critically, unlike benzodiazepine treatment, Selank administration was not associated with sedation, psychomotor impairment, or cognitive decline as measured by neuropsychological testing performed during the treatment period. Several studies specifically reported improvements in attention and mental clarity measures despite — or perhaps because of — the anxiety reduction, consistent with the compound’s BDNF-mediated nootropic mechanism. These findings have informed the compound’s approval status in Russia for anxiety disorders, though they have not yet been replicated in large, multi-center, double-blind trials meeting contemporary Western regulatory standards.
A body of research, both preclinical and in human volunteers, has examined Selank’s effects on cognitive function independent of its anxiolytic activity. In animal models using standard spatial memory and associative learning tasks (Morris water maze, radial arm maze, passive avoidance paradigms), Selank-treated animals consistently outperform vehicle controls on measures of learning acquisition speed and memory consolidation. These effects are observed in normal animals, not only in models of cognitive impairment, suggesting genuine cognitive enhancement rather than simply restoration of stress-impaired function.
In human studies, cognitive effects have been most clearly demonstrated under conditions of stress — examination-period studies in students, for instance, have found that Selank treatment maintains cognitive performance metrics that decline in control groups under academic stress. This stress-buffering effect on cognition is consistent with both the BDNF mechanism (BDNF supports hippocampal function and is suppressed by chronic stress) and the anxiety reduction mechanism (anxiety consumes working memory and attentional resources, so its reduction liberates cognitive capacity). Disentangling these contributions — whether Selank enhances cognition directly or secondarily through anxiety reduction — remains methodologically challenging and is an open research question.
Retaining the tuftsin backbone means Selank inherits the immunostimulatory properties of its parent peptide, and the extended structure appears to preserve rather than diminish this activity. Tuftsin was originally characterized as a macrophage-activating factor that enhances phagocytic activity, and Selank has been shown to share this property in both in vitro cell culture studies and in vivo animal models. Macrophage activation by Selank involves increased phagocytic index, enhanced respiratory burst activity, and upregulation of surface expression of receptors important for antigen recognition and pathogen clearance.
Research has also documented effects on cytokine production profiles. Studies examining Selank’s effects on IL-6, interferon-gamma, and TNF-alpha found complex bidirectional modulation — in states of immune hyperactivation (such as inflammatory conditions), Selank tends to suppress pro-inflammatory cytokines; in states of immune suppression (such as post-operative immunosuppression or experimental immunodeficiency), it tends to upregulate protective immune responses. This homeostatic immunomodulatory character, rather than simple immunostimulation or immunosuppression, may explain the compound’s interest to researchers working on stress-induced immune dysregulation, where anxiety disorders and immune dysfunction frequently co-occur. The mechanistic intersection of Selank’s CNS-anxiolytic and peripheral-immune effects is not coincidental — the tuftsin receptor is expressed in both peripheral immune cells and brain microglia, suggesting a unified mechanism operating in both compartments.
Several published studies have directly compared Selank to benzodiazepine reference compounds in both animal models and clinical settings, providing head-to-head data rather than relying on indirect comparison across studies. In rodent models using standard anxiety paradigms (elevated plus maze, open field, Vogel conflict test), Selank at doses of 100-400 mcg/kg produced anxiolytic effects comparable in magnitude to those of diazepam at standard reference doses. The critical differentiating finding was in the measures of sedation and cognitive performance: diazepam-treated animals showed dose-dependent motor impairment and reduced exploratory behavior, while Selank-treated animals showed no motor impairment and maintained or exceeded control-group exploratory behavior — consistent with the absence of sedation reported in human studies.
In clinical comparative studies, Selank and low-dose oxazepam (a short-acting benzodiazepine) were compared in GAD patients over a 10-14 day treatment period. Anxiety reduction was comparable between groups, but the Selank group showed significantly better performance on neuropsychological measures of attention, memory, and processing speed administered mid-treatment and at end of treatment. The Selank group also showed no withdrawal anxiety or rebound symptom increase in the post-treatment assessment period, while a proportion of oxazepam-treated patients showed symptom rebound consistent with the mild physical dependence that develops within 1-2 weeks of benzodiazepine use. These findings have significant implications for clinical anxiety treatment research and for the design of future comparative effectiveness studies.
Beyond its effects on manifest anxiety, Selank has been studied for its ability to enhance stress resilience — the capacity to cope with stressors without developing pathological responses. Research in animal models of repeated stress (restraint stress, social defeat, unpredictable chronic mild stress) has found that Selank pre-treatment or concurrent treatment attenuates the development of anhedonia, hypercortisolemia, and behavioral despair that characterize chronic stress models. These effects extend beyond simple anxiolysis and suggest that Selank may shift the neurobiological set point for stress response, rather than merely suppressing its expression. The BDNF mechanism is a plausible substrate for this effect, as BDNF is a key molecular mediator of stress resilience and its chronic elevation is associated with reduced vulnerability to stress-induced psychiatric conditions.
The most extensively studied dosing regimen for Selank in human subjects uses intranasal administration of 400-900 mcg per day, typically divided across 3-4 doses per day (roughly 100-250 mcg per administration). Russian clinical protocols used in the approval studies employed a 10-14 day treatment course, with daily doses in the 400-600 mcg range for the majority of subjects. The approved Russian formulation (0.15% solution) delivers approximately 45 mcg per drop, which allows dose titration through control of drop number. Animal model research has used a wide dose range, with 100-400 mcg/kg subcutaneous in rodents translating to approximately 10-40 mcg/kg in human equivalent dose (using standard allometric scaling), broadly consistent with the clinical doses used in human trials. Use the dosing calculator to work through weight-adjusted dose estimates for research planning.
Intranasal delivery is the primary and best-studied administration route for Selank, and it is the route used in the approved Russian formulation. The nasal mucosa provides a well-vascularized surface for systemic absorption, but the more pharmacologically relevant aspect of intranasal delivery for CNS-active peptides is direct transport via olfactory and trigeminal neural pathways to the brain, bypassing the blood-brain barrier. This direct CNS delivery pathway is thought to contribute to Selank’s relatively rapid onset of effect (typically 15-30 minutes intranasal versus several minutes with parenteral routes). Subcutaneous injection has been used in preclinical research and in some clinical investigations, providing more controlled bioavailability but sacrificing the convenience and nose-to-brain delivery advantage of the intranasal route. Oral administration is not pharmacologically viable for this peptide class due to rapid degradation by gastrointestinal proteases.
Research-grade Selank is typically supplied as a lyophilized powder requiring reconstitution. For intranasal use, bacteriostatic water or sterile saline is used as the diluent, with target concentrations typically in the range of 0.1-0.3% (1-3 mg/mL) to allow accurate dose delivery via nasal spray pumps calibrated to deliver known volumes per actuation. Reconstituted peptide solution should be stored refrigerated at 2-8°C in amber or light-protected containers; stability studies support use within 28-30 days of reconstitution under these conditions. Lyophilized Selank powder maintains potency for extended periods when stored at -20°C in a desiccated environment, protected from freeze-thaw cycling. The peptide database contains stability and storage data from published studies for reference.
Published clinical research has used fixed-duration treatment courses (10-14 days) rather than indefinite ongoing use, and the animal model literature does not provide strong evidence that chronic continuous use produces cumulative benefit beyond the treatment window in most studied applications. Research protocols for anxiety applications have typically used 10-14 day courses with a treatment-free interval before re-evaluation. Whether longer treatment courses produce greater or more durable benefits, and whether the absence of identified tolerance development means indefinite use is feasible, are open research questions. For stress resilience and nootropic applications, episodic use during high-stress periods (academic examination periods, for instance, have been used as a model in human research) is supported by published data. Researchers designing Selank protocols may find the AI coach helpful for reviewing specific application contexts in the literature.
The safety profile of Selank as documented in published clinical trials has been remarkably clean for a pharmacologically active CNS compound. The most commonly noted adverse effects in Russian clinical trials were mild and transient: local nasal irritation or discomfort associated with intranasal delivery (reported in a minority of subjects), mild sedation in a small subset (notably less frequently than with benzodiazepine comparators), and occasional mild headache. Systemic adverse effects were not prominent in trial reports, which included standard laboratory assessments and vital sign monitoring. The absence of significant adverse events across multiple studies and the favorable comparison to benzodiazepines in direct comparative trials have contributed to Selank’s approved status in Russia as a moderately-regulated over-the-counter anxiolytic, a regulatory classification that reflects an assessment of meaningful safety margin.
One of the most clinically significant safety features of Selank relative to benzodiazepines is the absence of identified physical dependence or withdrawal phenomena in published research. Studies that include post-treatment follow-up assessments have not found evidence of rebound anxiety, withdrawal anxiety, or physical withdrawal symptoms following discontinuation of 10-14 day treatment courses. The mechanistic basis for this — Selank’s indirect modulation of GABA-A receptor function versus benzodiazepines’ direct allosteric potentiation, and Selank’s BDNF/enkephalin mechanisms that do not involve the receptor downregulation and tolerance development characteristic of benzodiazepine use — provides a biological rationale consistent with the clinical observation. However, it is important to note that most published studies use relatively short treatment courses; the dependence profile of very long-duration (months to years) Selank use has not been systematically characterized in human research.
While the published safety data for Selank are encouraging, several important limitations should be acknowledged. The clinical trial literature is almost entirely from Russian research groups, and many studies lack the methodological features (blinding quality, independent monitoring, pre-registered protocols) required for high-confidence safety assessments by contemporary Western regulatory standards. Sample sizes in individual studies have generally been modest, limiting statistical power to detect uncommon adverse events. The long-term safety of Selank — particularly with respect to sustained BDNF modulation, enkephalinase inhibition effects, and immune modulation — has not been studied in trials exceeding several weeks in duration. Selank’s immunostimulatory activity via the tuftsin mechanism means caution is appropriate in individuals with autoimmune conditions, where immune stimulation could theoretically exacerbate disease activity. Drug interaction data is largely absent from the published literature, and interactions with other CNS-active agents — particularly benzodiazepines, SSRIs, and opioids — have not been systematically characterized in human subjects.
Clinical and anecdotal reports consistently describe a relatively rapid onset of anxiolytic effect with intranasal Selank — typically within 15-30 minutes of administration. This fast onset distinguishes it from SSRIs and SNRIs, which require weeks of daily use before therapeutic effects emerge, and is more comparable to the onset profile of benzodiazepines. The rapid onset is attributed in part to the nose-to-brain delivery pathway used by intranasal administration, which allows CNS delivery without waiting for systemic circulation and blood-brain barrier traversal. Research studies measuring acute anxiolytic effects have used assessment windows of 30-120 minutes post-administration and consistently found significant reductions in anxiety measures within this timeframe.
This is one of the most common questions in Selank research and deserves a nuanced answer. The evidence from direct comparative studies suggests that Selank produces comparable anxiety reduction to low-dose benzodiazepines with a more favorable cognitive profile and no identified dependence risk. However, these studies have generally used relatively short treatment courses in GAD populations; Selank has not been studied in severe anxiety states, panic disorder, or acute anxiety requiring rapid control, and it has not been directly compared to higher therapeutic doses of benzodiazepines in severe anxiety. For research purposes, Selank appears to occupy a niche as a gentler, cognitively-sparing anxiolytic appropriate for mild-to-moderate generalized anxiety — it is not established as a replacement for benzodiazepines in all anxiety contexts, and anyone currently using prescribed benzodiazepines should not discontinue without medical supervision.
Neither, in the conventional sense. The consistent finding across animal and human studies is that Selank is anxiety-reducing without being sedating. It does not increase locomotor activity or produce the psychomotor stimulation associated with classical stimulant compounds. It also does not produce the sedation, muscle relaxation, or cognitive slowing associated with benzodiazepines. Human study participants describe the subjective effect as a quieting of anxious rumination with preservation of — and sometimes enhancement of — mental clarity and focus. This profile places Selank in the relatively rare category of “anxioselective” compounds, where anxiety reduction is achieved without the sedation that is the primary mechanism and primary adverse effect of most available anxiolytics.
Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide produced by enzymatic cleavage of immunoglobulin G in the spleen, with established immunostimulatory properties including enhancement of phagocytic activity and NK cell function. Selank was created by adding the tripeptide Pro-Gly-Pro to the C-terminus of tuftsin, producing a heptapeptide with dramatically improved metabolic stability (tuftsin itself is very rapidly cleaved in plasma) and a substantially expanded pharmacological profile that includes the anxiolytic and nootropic effects absent from the parent compound. The added sequence is not arbitrary — Pro-Gly-Pro appears in various endogenous peptides and has known CNS activity — but the precise mechanism by which the C-terminal extension adds CNS activity to the tuftsin backbone is not fully characterized at the molecular level.
Yes, and positively. Studies in both animal models and human subjects consistently find that Selank has beneficial effects on learning and memory. In rodent experiments using standard spatial learning paradigms, Selank-treated animals show faster acquisition and better retention compared to vehicle controls. In human studies, Selank treatment is associated with maintained or improved performance on neuropsychological tests of attention, working memory, and recall, particularly under stress conditions. The BDNF-TrkB mechanism provides a compelling molecular explanation: BDNF elevation in the hippocampus facilitates long-term potentiation (the synaptic mechanism underlying memory formation) and supports hippocampal neurogenesis, both of which contribute to learning and memory capacity. Unlike the cognitive suppression seen with benzodiazepines, Selank’s cognitive effects are in the opposite direction.
Selank and Semax are both Russian-developed research peptides with CNS-active and nootropic properties, but they differ substantially in origin, mechanism, and primary application. Semax is derived from the ACTH(4-10) sequence and works primarily through upregulation of BDNF, NGF, and related neurotrophins via multiple growth factor pathways, with its primary studied applications in neuroprotection and cognitive enhancement. Selank is derived from tuftsin and has its most established mechanism in anxiolysis via GABA-A modulation, enkephalin metabolism, and BDNF. While both compounds increase BDNF, Semax’s effects are broader and more potent across the neurotrophin landscape, while Selank’s additional anxiolytic and immunostimulatory mechanisms make it more targeted for stress-anxiety-immune applications. In the research literature, Semax is often studied for stroke recovery and neurological conditions while Selank is studied for anxiety and stress resilience. Both are covered in depth in the peptide database.
Available research does not identify addiction or physical dependence as risks associated with Selank use at doses studied in published trials. The compound’s mechanisms — BDNF modulation, enkephalin metabolism, GABA-A interaction — are distinct from those that drive addiction potential in classical substances. Importantly, while Selank modulates enkephalin degradation (increasing endogenous opioid tone), this mechanism is self-limiting because it depends on endogenous enkephalin release rather than providing exogenous opioid receptor agonism; this is fundamentally different from opioid drugs that directly activate reward circuitry. The absence of tolerance development in published studies also argues against addiction liability. However, definitive conclusions about long-term use would require systematic study beyond the trial durations in the current literature.
Selank’s immune-modulatory effects — derived from the tuftsin backbone — have been studied most thoroughly in the context of stress-related immune suppression. Psychological stress is well-established as a cause of impaired immune function, and Selank’s dual anxiolytic-immunostimulatory profile makes it theoretically well-suited for stress-associated immunodeficiency. Published research has also examined its effects in post-operative immune suppression and in viral infection models (including influenza models in animals), where its immunostimulatory properties showed protective effects. The cytokine-normalizing properties documented in human anxiety disorder studies suggest potential relevance for conditions where inflammatory cytokine dysregulation contributes to pathology. Autoimmune conditions represent a potential concern rather than an indication, given the immunostimulatory mechanism. Researchers interested in specific immune applications should consult the AI coach for guidance on the relevant literature.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.